Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
Sophie E. Willis, C Winkler, Martine P. Roudier, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 12, pp. 1666-1676
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime Haro-Silerio, Timothy A. Yap, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 6, pp. 904-916
Open Access | Times Cited: 75
Small cell lung cancer: Subtypes and therapeutic implications
Walter Wang, Alyssa Shulman, Joseph M. Amann, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 543-554
Closed Access | Times Cited: 45
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B. Allred, Li Chen, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4154-4163
Closed Access | Times Cited: 25
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis
Akane Ogawa, Keiichi Izumikawa, Sota Tate, et al.
Molecular Cell (2025)
Open Access | Times Cited: 1
The Landscape of PARP Inhibitors in Solid Cancers
Marta Muzzana, Massimo Broggini, Giovanna Damia
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 297-317
Open Access | Times Cited: 1
Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
Hiroshi Onji, Junko Murai
Cancer Science (2022) Vol. 113, Iss. 9, pp. 2943-2951
Open Access | Times Cited: 23
The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer
Daniela Scattolin, Alessandro Dal Maso, Alessandra Ferro, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102768-102768
Closed Access | Times Cited: 6
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks
Hiroshi Onji, Sota Tate, Tomohisa Sakaue, et al.
Oncogene (2024) Vol. 43, Iss. 32, pp. 2475-2489
Open Access | Times Cited: 5
Strategies for the prevention or reversal of PARP inhibitor resistance
Zahi Mitri, Shaun Goodyear, Gordon B. Mills
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 10, pp. 959-975
Open Access | Times Cited: 4
Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance
Satoru Kyo, Kosuke Kanno, Masahiro Takakura, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2504-2504
Open Access | Times Cited: 19
PARP Inhibitors as Therapy for Small Cell Lung Carcinoma: A Systematic Review and Meta-Analysis of Clinical Trials
Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, et al.
Cancer Treatment and Research Communications (2025), pp. 100874-100874
Open Access
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Quincy Chu
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 252-255
Closed Access
MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors
Maciej Kaczorowski, Małgorzata Chłopek, Ondřej Daum, et al.
The Journal of Pathology Clinical Research (2025) Vol. 11, Iss. 2
Open Access
Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis
Sajjad Hajihosseini, Elham Emami, Seyed Rasoul Zakavi, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Takeaki Nakamura, Kanako C. Hatanaka, Y. Kawamoto, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 5
Open Access
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
Jiaqi Xiong, Ranya Barayan, Alexander V. Louie, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 521-542
Open Access | Times Cited: 16
The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13
Kohei Fujiwara, Masashi Maekawa, Yuki Iimori, et al.
iScience (2023) Vol. 26, Iss. 12, pp. 108529-108529
Open Access | Times Cited: 8
DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review
Zoe Phan, Caroline E. Ford, C. Elizabeth Caldon
Pharmacological Research (2023) Vol. 196, pp. 106927-106927
Open Access | Times Cited: 7
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy
Ozen Leylek, Megan E. Honeywell, Michael J. Lee, et al.
Gastric Cancer (2024) Vol. 27, Iss. 6, pp. 1201-1219
Open Access | Times Cited: 2
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Jing Zhang, Xiaoping Zeng, Qiji Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets
Maciej Kaczorowski, Kris Ylaya, Małgorzata Chłopek, et al.
The American Journal of Surgical Pathology (2024) Vol. 48, Iss. 12, pp. 1512-1521
Closed Access | Times Cited: 2
Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Junko Murai, Michele Ceribelli, Haiqing Fu, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 8, pp. 985-995
Open Access | Times Cited: 5
SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 1, pp. 106-116
Closed Access | Times Cited: 5
SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells
Philipp König, Julia Maria Eichhorn, Eloy Suparman, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 8, pp. 167448-167448
Open Access | Times Cited: 1
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence
Fatemeh Moosavi, Bahareh Hassani, Somayeh Nazari, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189185-189185
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top